TKT and glioblastoma: Consistent with our findings, it has been reported in the GL26 GBM mouse model that TMZ (100 mg/kg) plus Ad-TK+Ad-Flt3L gene therapy prolonged the animal survival despite the reduced T-cell infiltration 44.